Barrett’s Esophagus – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report

Barrett’s Esophagus (BE) represents a pre-cancerous state characterized by transforming normal esophageal squamous epithelium into metaplastic columnar epithelium. Most patients with BE have a documented history of chronic gastroesophageal reflux disease (GERD), involving the regurgitation of stomach and bile acids through the lower esophageal sphincter into the distal esophagus. While the precise pathogenesis of BE remains incompletely understood, progress has been made in elucidating the molecular changes and primary cell types involved. Research suggests that acid exposure prompts squamous epithelial cells to release inflammatory cytokines such as IL8 and IL1b, initiating an inflammatory cascade that recruits T lymphocytes and neutrophils into the epithelial layer. Bile acids, in particular, have been shown to upregulate CDX2, a factor for intestinal differentiation, and MUC2, a gene specific to goblet cells, in both normal columnar and esophageal cancer cell lines. Diagnosis of BE necessitates endoscopic identification of columnar metaplasia, typically described as “salmon-pink” patches of mucosal tissue, and histological confirmation of intestinal metaplasia featuring goblet cells upon biopsy examination. Cryotherapy presents an alternative ablative therapy option. Following ablative therapy, continued surveillance of patients is essential as multiple treatments are often needed to ensure complete eradication of the affected tissue. In cases where no mucosal abnormalities are visible, radiofrequency ablation therapy is deemed appropriate for addressing low- or high-grade dysplasia and carcinoma. Cryotherapy serves as an additional ablative therapy modality.

Thelansis’s “Barrett’s Esophagus Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033″ covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Barrett’s Esophagus treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
KOLs insights of Barrett’s Esophagus across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.
Barrett’s Esophagus Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.
Read more: Barrett’s Esophagus – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033